Home Cart Sign in  
Chemical Structure| 856013-04-2 Chemical Structure| 856013-04-2

Structure of 856013-04-2

Chemical Structure| 856013-04-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 856013-04-2 ]

CAS No. :856013-04-2
Formula : C5H5BrN2O2S
M.W : 237.07
SMILES Code : O=S(C1=NC(Br)=CC=C1)(N)=O
MDL No. :MFCD14702808
InChI Key :WAYSQXHNUWIYPM-UHFFFAOYSA-N
Pubchem ID :57345816

Safety of [ 856013-04-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 856013-04-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 42.93
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

81.43 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.14
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.77
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.57
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.52
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.26
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.65

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.13
Solubility 1.75 mg/ml ; 0.00737 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.06
Solubility 2.06 mg/ml ; 0.0087 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.45
Solubility 0.841 mg/ml ; 0.00355 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.2 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.1

Application In Synthesis of [ 856013-04-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 856013-04-2 ]

[ 856013-04-2 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 856013-03-1 ]
  • [ 856013-04-2 ]
YieldReaction ConditionsOperation in experiment
ii) 6-Bromopyridine-2-sulfonamide 6-Bromopyridine-2 (1H)-thione (114 mg) was added to a mixture of bromine (0.061 ml) in water (3.6 ml) and ice (1.8g) and the mixture was stirred at 0C for 2 h. Aqueous ammonia (2 ml) was added and the mixture was stirred for 1 h at 20 C and then heated to reflux. The reaction mixture was filtered while hot and then allowed to crystallise. The solid was collected by filtration and then purified by chromatography on a 10 g silica SPE cartridge eluting with ethyl acetate-cyclohexane (3: 2) to give the title comound (63mg) LCMS RT=1. 6 min
  • 2
  • [ 856013-04-2 ]
  • [ 1135871-91-8 ]
  • [ 1135871-90-7 ]
YieldReaction ConditionsOperation in experiment
With potassium carbonate;bis-triphenylphosphine-palladium(II) chloride; tetrabutylammomium bromide; In 1,4-dioxane; water; at 100℃; for 1h;Microwave irradiation; c) 6-(8-Oxo-5,6,7,8-tetrahydro-naphthalen-2-yl)-pyridine-2-sulfonamide6-Bromo-pyridine-2-sulfonamide (65mg, 0.27 mmol), 7-(4,4,5,5-Tetramethyl- [l,3,2]dioxaborolan-2-yl)-3,4-dihydro-2H-naphthalen-l-one (97mg, 0.36 mmol), tetrabutylammonium bromide (TBAB) (lOmg, 0.04 mmol) and Pd(PPh3)2Cl2 (13mg, 0.02 mmol) in dioxane:water (1.2 mL/0.6 mL) were heated at 1000C in a microwave reactor for 1 hour. After this time, water was added and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed with water and brine and dried over Na2SO4. Concentration afforded a brown solid which was triturated with Et2O. An off-white solid was obtained. Analysis (NMR) showed presence of impurities but the compound was on-reacted without further purification. NMR 1H (d6-DMSO, ppm): 8.6 (d, J = 2.1 Hz, IH), 8.36 (dd, J = 8.1 and 2.1 Hz, IH), 8.20 (dd, J = 9.03 and 1 Hz, IH), 8.11 (t, J = 7.6 Hz, IH), 7.85 (dd, J = 7.6 and 1 Hz, IH), 7.53-7.50 (m, 3H), 3.01-2.98 (m, 2H), 2.66-2.62 (m, 2H), 2.10-2.04 (m, 2H).
  • 3
  • [ 1135871-89-4 ]
  • [ 856013-04-2 ]
YieldReaction ConditionsOperation in experiment
32% With trifluoroacetic acid; at 60℃; for 3h; b) 6-Bromo-pyridine-2-sulfonamideTFA (2 mL) was added to 6-bromo-pyridine-2-(N-fert-butyl)-sulfonamide (478mg, 1.63 mmol) and the reaction was stirred at 6O0C for 3 hours. TFA was removed under vacuum and a mixture of Petroleum ether and Et2O was added leading to the precipitation of a brown solid. It was collected and triturated three times with Et2O. A white solid was obtained (125mg, 32%). NMR 1H (de-DMSO, ppm): 7.98 (t, J = 7.5 Hz, IH), 7.91 (dd, J = 7.5 and 1.2 Hz, IH), 7.87 (dd, J = 7.5 and 0.9 Hz, IH).
  • 4
  • [ 856013-04-2 ]
  • [ 75-36-5 ]
  • [ 1353560-12-9 ]
YieldReaction ConditionsOperation in experiment
85% With potassium carbonate; In acetonitrile; at 20℃; for 16h;Cooling; <strong>[856013-04-2]6-Bromopyridine-2-sulphonamide</strong> (0.5 g, 2.11 mmol, prepared by the methods described in WO2005/058299) and potassium carbonate (2.92 g, 21.1 mmol) were initially charged in acetonitrile (10 ml). While cooling with ice, acetyl chloride (1.16 g, 14.8 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure, and the residue was taken up in water and acidified with dilute hydrochloric acid solution. It was extracted with ethyl acetate and the solvent was removed under reduced pressure. This gave 0.54 g (85% of theory) of N-[(6-bromopyridin-2-yl)sulphonyl]-acetamide.HPLC-MS: LogP(HCOOH): 0.95; mass (m/z): 278.9 (M+H)+;1H NMR (d6-DMSO): 1.99 (s, 3H), 7.99-8.01 (m, 1H), 8.08 (t, 1H), 8.11-8.13 (m, 1H), 12.48 (s, 1H) ppm.
  • 5
  • [ 856013-04-2 ]
  • [ 1353559-33-7 ]
  • 6
  • [ 856013-04-2 ]
  • [ 1286202-05-8 ]
  • [ 1353560-13-0 ]
YieldReaction ConditionsOperation in experiment
97% With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In water; acetonitrile; at 70℃; for 18h;Inert atmosphere; Under argon, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]pyridine (0.2 g, 0.74 mmol, prepared by the methods described in WO 2011/045224), 6-bromopyridin-2-sulphonamide (0.175 g, 0.74 mmol) and tetrakis(triphenylphosphine)palladium (0.025 g, 0.022 mmol) were added to a mixture, degassed by means of argon, of sodium carbonate solution in water (2.9 ml, 2 M/L) and acetonitrile (4 ml). The reaction mixture was stirred at 70 C. for 18 h. After cooling, the reaction mixture was poured onto water and the precipitated crystals were filtered off with suction. They were subsequently stirred with diethyl ether and filtered off with suction. This gave 0.23 g (97% of theory) of 6-[1-(pyridin-3-yl)-1H-pyrazol-4-yl]pyridine-2-sulphonamide.HPLC-MS: LogP(HCOOH): 0.99; mass (m/z): 302.1 (M+H)+ 1H NMR (d6-DMSO): 7.43 (s, 2H), 7.60-7.63 (m, 1H), 7.76 (d, 1H), 8.00 (d, 1H), 8.11 (t, 1H), 8.28-8.31 (m, 1H), 8.53 (s, 1H), 8.58-8.60 (m, 1H), 9.16-9.17 (m, 1H), 9.33 (s, 1H) ppm
  • 7
  • [ 626-05-1 ]
  • [ 856013-04-2 ]
  • 8
  • [ 93681-52-8 ]
  • [ 856013-04-2 ]
  • 9
  • [ 912934-77-1 ]
  • [ 856013-04-2 ]
  • 10
  • [ 856013-04-2 ]
  • [ 1272353-93-1 ]
  • 6-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridine-2-sulfonamide [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 856013-04-2 ]

Bromides

Chemical Structure| 912934-77-1

A132245 [912934-77-1]

6-Bromopyridine-2-sulfonyl chloride

Similarity: 0.71

Chemical Structure| 874959-68-9

A439298 [874959-68-9]

5-Bromopyridine-2-sulfonyl chloride

Similarity: 0.57

Amines

Chemical Structure| 63636-89-5

A168147 [63636-89-5]

Pyridine-2-sulfonamide

Similarity: 0.83

Chemical Structure| 65938-77-4

A230397 [65938-77-4]

5-Methyl-2-pyridinesulfonamide

Similarity: 0.77

Chemical Structure| 75903-58-1

A322579 [75903-58-1]

6-Aminopyridine-2-sulfonamide

Similarity: 0.76

Chemical Structure| 65938-79-6

A604749 [65938-79-6]

3-Methylpyridine-2-sulfonamide

Similarity: 0.74

Chemical Structure| 314250-03-8

A194461 [314250-03-8]

N,N-Diethylpyridine-2-sulfonamide

Similarity: 0.67

Sulfamides

Chemical Structure| 63636-89-5

A168147 [63636-89-5]

Pyridine-2-sulfonamide

Similarity: 0.83

Chemical Structure| 65938-77-4

A230397 [65938-77-4]

5-Methyl-2-pyridinesulfonamide

Similarity: 0.77

Chemical Structure| 75903-58-1

A322579 [75903-58-1]

6-Aminopyridine-2-sulfonamide

Similarity: 0.76

Chemical Structure| 65938-79-6

A604749 [65938-79-6]

3-Methylpyridine-2-sulfonamide

Similarity: 0.74

Chemical Structure| 314250-03-8

A194461 [314250-03-8]

N,N-Diethylpyridine-2-sulfonamide

Similarity: 0.67

Related Parent Nucleus of
[ 856013-04-2 ]

Pyridines

Chemical Structure| 63636-89-5

A168147 [63636-89-5]

Pyridine-2-sulfonamide

Similarity: 0.83

Chemical Structure| 65938-77-4

A230397 [65938-77-4]

5-Methyl-2-pyridinesulfonamide

Similarity: 0.77

Chemical Structure| 75903-58-1

A322579 [75903-58-1]

6-Aminopyridine-2-sulfonamide

Similarity: 0.76

Chemical Structure| 65938-79-6

A604749 [65938-79-6]

3-Methylpyridine-2-sulfonamide

Similarity: 0.74

Chemical Structure| 912934-77-1

A132245 [912934-77-1]

6-Bromopyridine-2-sulfonyl chloride

Similarity: 0.71